Common Themes Across Tumor Types

Dr. Teplinsky, reflecting on commonalities across tumor types, notes that although the discussion focused on early-stage breast cancer, increasing ctDNA use exists in metastatic disease to identify treatment-emergent mutations guiding therapy selection, representing a different application context.

She observes that challenges discussed are remarkably similar across tumor types: data needs, result interpretation, de-escalation and intensification questions, and access barriers.

Although research maturity differs by cancer type based on where each field is in the research process, the underlying questions and needs remain consistent, raising the possibility that tumor-agnostic research approaches might help advance the field collectively across disease types.

Dr. Weinberg identifies important commonalities around imaging intensification effects on surveillance and adjuvant therapy decisions, while emphasizing critical differences in tumor shedding patterns.

Colorectal and breast cancers represent high-shedding tumors, whereas pancreatic cancer sheds substantially less, creating false-negative results where tumors exist but aren't detectable in bloodstream due to mutational burden, disease burden, and tumor biology differences.

He cautions against cross-disease comparisons even using identical assays, while affirming the technology's broad applicability across solid tumors given increasing biomarker-directed therapy approaches requiring understanding of individual tumor genomic composition, ideally before metastatic progression occurs.

He notes this represents where the field is moving: toward better understanding the genomics of localized tumors before they become metastatic, applying lessons learned across disease types while respecting tumor-specific shedding biology.